Search results for "antidepressant"

showing 10 items of 161 documents

Minimum effective dose for antidepressants - an obligatory requirement for antidepressant drug evaluation?

1996

Extensive clinical trials are required for registration and approval of new antidepressants in most countries including the requirement that a minimal effective dose should be determined. The rationale for this requirement is to avoid the use of unnecessarily high doses. The implication is that for every antidepressant, a dose exists that serves as a threshold, below which all doses are not effective or are clearly less effective in treating a major depressive episode. Dose titration and fixed dose studies are used to determine the minimal effective dose, but both strategies have limitations and often do not allow definite establishment of a clear-cut minimal effective dose. The effort of e…

Drugmedicine.medical_specialtymedia_common.quotation_subjectComorbidityPharmacologyPharmacokineticsmedicineHigh dosesHumansEthics MedicalPharmacology (medical)Intensive care medicineMajor depressive episodemedia_commonClinical Trials as TopicDepressive DisorderDose-Response Relationship Drugbusiness.industryConfounding Factors EpidemiologicEffective dose (pharmacology)Antidepressive AgentsClinical trialPsychiatry and Mental healthSample size determinationAntidepressantmedicine.symptombusinessInternational Clinical Psychopharmacology
researchProduct

Therapeutic drug monitoring for antidepressant drug treatment.

2012

The aim of antidepressant drug treatment is to produce remission without causing adverse effects during the acute phase of the illness and to prevent relapses or recurrences during continuation or maintenance therapy. To achieve these goals, drug choice and dosage must be optimized for each patient individually. Therapeutic drug monitoring (TDM), which is based on the assumption that clinical effects correlate better with blood levels than doses, can be helpful. When using tricyclic antidepressant drugs TDM enhances safety and efficacy. For newer antidepressant drugs, however, it is a matter of debate to which extend TDM can have beneficial effects. For many antidepressants there exist care…

Drugmedicine.medical_specialtymedia_common.quotation_subjectCost-Benefit AnalysisPharmacologyDrug CostsDrug treatmentPharmacokineticsMaintenance therapyDrug DiscoveryPharmacovigilancemedicineSecondary PreventionHumansAdverse effectIntensive care medicinemedia_commonPharmacologymedicine.diagnostic_testbusiness.industryDepressionRemission InductionAntidepressive AgentsTreatment OutcomeTherapeutic drug monitoringAntidepressantDrug MonitoringbusinessCurrent pharmaceutical design
researchProduct

Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidep…

2021

Contains fulltext : 238693.pdf (Publisher’s version ) (Open Access) Objectives: More than 40 drugs are available to treat affective disorders. Individual selection of the optimal drug and dose is required to attain the highest possible efficacy and acceptable tolerability for every patient.Methods: This review, which includes more than 500 articles selected by 30 experts, combines relevant knowledge on studies investigating the pharmacokinetics, pharmacodynamics and pharmacogenetics of 33 antidepressant drugs and of 4 drugs approved for augmentation in cases of insufficient response to antidepressant monotherapy. Such studies typically measure drug concentrations in blood (i.e. therapeutic …

Drugmedicine.medical_specialtyprecision medicinetherapeutic drug monitoringmedia_common.quotation_subjectStress-related disorders Donders Center for Medical Neuroscience [Radboudumc 13]brain imagingNeuroimagingPsykiatri03 medical and health sciences0302 clinical medicinePharmacotherapyNeuroimagingmedicineHumansIntensive care medicineBiological Psychiatrypharmacogeneticsmedia_commonPsychiatrymedicine.diagnostic_testbusiness.industryAntidepressantsPrecision medicineAntidepressive Agents030227 psychiatryPsychiatry and Mental healthTherapeutic drug monitoringPharmacogeneticsAntidepressants; brain imaging; pharmacogenetics; precision medicine; therapeutic drug monitoring; Antidepressive Agents; Drug Monitoring; Humans; Neuroimaging; Pharmacogenetics; PsychiatryAntidepressants; brain imaging; precision medicine; pharmacogenetics; therapeutic drug monitoringDrug MonitoringbusinessPharmacogeneticsWorld Journal of Biological Psychiatry
researchProduct

Effects of acute amitriptyline administration on memory, anxiety and activity in male and female mice

2002

The effects of acute administration of amitriptyline on memory consolidation in male and female CD1 mice were investigated. Three doses of this tricyclic antidepressant (7.5, 15 and 30 mg/kg) were administered immediately after inhibitory avoidance training. Forty-five minutes after injection, subjects explored the elevated plus-maze for five minutes. Subjects were tested for avoidance twenty-four hours later. Amitriptyline impaired inhibitory avoidance consolidation at doses 7.5, 15 and 30 mg/kg in males, and at doses 7.5 and 30 mg/kg in females. In the elevated plus-maze, amitriptyline had no effect on anxiety (percentage of open arm entries) and induced a dose-dependent impairment of act…

Elevated plus mazemedicine.medical_specialtymedicine.drug_classGeneral NeuroscienceTricyclic antidepressantRetrograde amnesiaInhibitory postsynaptic potentialmedicine.diseaseAnxiolyticEndocrinologyAnesthesiaInternal medicinemedicineAnxietyMemory consolidationAmitriptylinemedicine.symptomPsychologymedicine.drugNeuroscience Research Communications
researchProduct

Assaying waterborne psychoactive drugs by the response to naturalistic predator cues in the stickleback (Gasterosteus aculeatus)

2020

Abstract Ecotoxicological effects of psychiatric drugs and drug metabolites released by the human population are of increasing environmental concern. In this study we evaluate behavioral responses to visual predator cues in wild caught three-spined stickleback (Gasterosteus aculeatus) after exposure to water-born citalopram, a widely prescribed selective serotonin reuptake inhibitor with antidepressant and anxiolytic effects. Fish were exposed to ecological relevant concentrations of citalopram (0.15 or 1.5 μg L−1) for 10 or 20 days. After drug exposure, individual fish were moved to a test arena where they were exposed to two naturalistic visual predator cues; a shadow from beneath, which …

Environmental Engineering010504 meteorology & atmospheric sciencesSerotonin reuptake inhibitorPopulationZoologyGasterosteusCitalopram010501 environmental sciencesCitalopramStimulus (physiology)01 natural sciencesmedicineAnimalsEnvironmental ChemistryeducationWaste Management and DisposalSensory cue0105 earth and related environmental scienceseducation.field_of_studybiologySticklebackbiology.organism_classificationPollutionSmegmamorphaAnti-Anxiety AgentsAntidepressantCuesSelective Serotonin Reuptake Inhibitorsmedicine.drug
researchProduct

Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders.

2021

Introduction The aim of this study was to describe the number and type of drugs used to treat depressive disorders in inpatient psychiatry and to analyse the determinants of potential drug-drug interactions (pDDI) and potentially inappropriate medication (PIM). Methods Our study was part of a larger pharmacovigilance project funded by the German Innovation Funds. It included all inpatients with a main diagnosis in the group of depressive episodes (F32, ICD-10) or recurrent depressive disorders (F33) discharged from eight psychiatric hospitals in Germany between 1 October 2017 and 30 September 2018 or between 1 January and 31 December 2019. Results The study included 14,418 inpatient cases.…

Epidemiologymedicine.medical_treatment0302 clinical medicineRisk FactorsMedicine and Health SciencesAntipsychoticsDrug Interactions030212 general & internal medicineDepression (differential diagnoses)Potentially Inappropriate Medication Listmedia_commonMultidisciplinaryDepressionPharmaceuticsQRDrugsAntidepressantsMiddle AgedAntidepressive AgentsAntidepressant Drug TherapyMedicineAntidepressantDrug Therapy CombinationAntipsychotic AgentsResearch ArticleDrugNeurological Drug Therapymedicine.medical_specialtyPatientsSciencemedia_common.quotation_subject03 medical and health sciencesPharmacotherapyDrug TherapyInternal medicinePharmacovigilanceMental Health and PsychiatrymedicineHumansAntipsychoticProbabilityPolypharmacyPharmacologyInpatientsbusiness.industryMood DisordersOdds ratioHealth CareLogistic ModelsMedical Risk Factorsbusiness030217 neurology & neurosurgeryReceptor Antagonist TherapyPloS one
researchProduct

Value of genetic and epigenetic testing as biomarkers of response to antidepressant treatment

2013

Major depressive disorder (MDD) is one of the most prevalent and disabling psychiatric disorders worldwide and therefore an important public health priority. The selection process of antidepressant treatment is primarily guided by trial and error, and the outcomes with current antidepressant strategies are disappointing. The biological background of the disease is heterogeneous with presumably multiple biological systems involved. With the aim to individualize antidepressant treatment, multiple candidate gene and a few genome-wide association studies have been performed, but so far with very limited success. To address the dynamic changes of depressive symptoms and their response to treatme…

EpigenomicsDepressive Disorder Majormedicine.medical_specialtyCandidate genemedicine.diagnostic_testDiseasemedicine.diseaseAntidepressive AgentsPsychiatry and Mental healthPharmacogeneticsmedicineHumansBiomarker (medicine)Major depressive disorderAntidepressantGenetic TestingPsychologyPsychiatryBiomarkersPharmacogeneticsEpigenomicsGenetic testingInternational Review of Psychiatry
researchProduct

Medicinal Plants in the Treatment of Depression. II: Evidence from Clinical Trials

2021

AbstractDepression is a syndrome characterized by deep sadness and the inhibition of psychic functions, sometimes accompanied by neurovegetative disorders, with symptoms of anxiety almost always present. The disease produces alterations in a variety of neural networks and neurotransmission systems, along with a dysfunction of the hypothalamic-pituitary-adrenal axis, which leads to concomitant alterations in the immunological response. Generally, there is a parallel increase in proinflammatory mediators as well as oxidative and nitrosative damage caused by a reduction of antioxidant defenses. In a previous review, we compiled and examined studies of medicinal plants that had been evaluated i…

Hypothalamo-Hypophyseal SystemPituitary-Adrenal SystemPharmaceutical ScienceDiseaseBioinformaticsAntioxidantsAnalytical Chemistry03 medical and health sciences0302 clinical medicineDrug DiscoveryHumansMedicineMedicinal plantsDepression (differential diagnoses)PharmacologyPlants MedicinalKavaDepressionbusiness.industryOrganic ChemistryAntidepressive Agents030227 psychiatryClinical trialSystematic reviewComplementary and alternative medicineMolecular MedicineAntidepressantAnxietymedicine.symptombusinessHypericum030217 neurology & neurosurgeryPhytotherapySystematic Reviews as TopicPlanta Medica
researchProduct

Neurotrophic Properties of Silexan, an Essential Oil from the Flowers of Lavender-Preclinical Evidence for Antidepressant-Like Properties.

2020

Abstract Background Silexan, a special essential oil from flowering tops of lavandula angustifolia, is used to treat subsyndromal anxiety disorders. In a recent clinical trial, Silexan also showed antidepressant effects in patients suffering from mixed anxiety-depression (ICD-10 F41.2). Since preclinical data explaining antidepressant properties of Silexan are missing, we decided to investigate if Silexan also shows antidepressant-like effects in vitro as well as in vivo models. Methods We used the forced swimming test (FST) in rats as a simple behavioral test indicative of antidepressant activity in vivo. As environmental events and other risk factors contribute to depression through conve…

Imipraminemedicine.drug_classSynaptogenesisCell Culture TechniquesPregabalinTricyclic antidepressantPharmacologyCREBImipramineRats Sprague-Dawley03 medical and health sciences0302 clinical medicinemedicineOils VolatileAnimalsPlant OilsPharmacology (medical)030304 developmental biology0303 health sciencesbiologyDose-Response Relationship Drugbusiness.industryGeneral MedicineCREB-Binding ProteinCyclic AMP-Dependent Protein KinasesAntidepressive AgentsRatsPsychiatry and Mental healthLavandulaSynaptic plasticitybiology.proteinAntidepressantbusiness030217 neurology & neurosurgerymedicine.drugBehavioural despair testNeurotrophinPharmacopsychiatry
researchProduct

Spectroscopic correlates of antidepressant response to sleep deprivation and light therapy: a 3.0 Tesla study of bipolar depression.

2007

Glutamate is the primary excitatory neurotransmitter of the human brain, and recent findings suggest a role for the glutamatergic system in the pathophysiology and treatment of mood disorders. Single proton magnetic resonance spectroscopy (1H-MRS) was used to study the relative in vivo levels of brain neural metabolites. We evaluated the effect of antidepressant treatments on the relative concentration of unresolved glutamate and glutamine (Glx) with GABA contamination (2.35 ppm peak) using single voxel 1H-MRS at 3.0 Tesla. We studied 19 inpatients (7 males, 12 females) affected by bipolar disorder type 1, current depressive episode without psychotic features, before and after 1 week of tre…

Light therapyAdultMalemedicine.medical_specialtyBipolar DisorderMagnetic Resonance Spectroscopymedicine.medical_treatmentNeuroscience (miscellaneous)Glutamic AcidCreatinechemistry.chemical_compoundInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingBipolar disorderSleep disorderGlutamate receptorBrainMiddle AgedPhototherapymedicine.diseaseCreatineMagnetic Resonance ImagingAntidepressive AgentsPsychiatry and Mental healthSleep deprivationEndocrinologychemistryMood disordersAntidepressantSleep DeprivationFemalemedicine.symptomProtonsPsychologyNeurosciencePsychiatry research
researchProduct